SEDT (spondyloepiphyseal dysplasia tarda) is a late-onset X-linked recessive skeletal dysplasia caused by mutations in the gene SEDL coding for sedlin. In the present paper, we investigated four missense mutations observed in SEDT and compare biochemical and cellular characteristics relative to the wild-type protein to address the mechanism of disease and to gain insight into the function of the sedlin protein. In situ hybridization and immunohistochemical experiments in mouse growth plates revealed sedlin to be predominantly expressed in proliferating and hypertrophic chondrocytes. Cell culture studies showed that the wildtype protein localized predominantly in the vicinity of the nucleus and the Golgi, with further localization around the cytoplasm, whereas mutation resulted in mislocalization. The D47Y mutant was expressed similarly to the wild-type, but the S73L, F83S and V130D mutants showed particularly low levels of expression that were rescued in the presence of the proteasome inhibitor MG132 (benzyloxycarbonyl-leucylleucylleucinal). Furthermore, whereas the D47Y mutant folded similarly and had similar stability to the wild-type sedlin as shown by CD and fluorescence, the S73L, F83S and V130D mutants all misfolded during expression. Two independent assays showed that the D47Y mutation resulted in an increased affinity for the transport protein particle component Bet3 compared with the wild-type sedlin. Our results suggest that the sedlin mutations S73L, F83S and V130D cause SEDT by sedlin misfolding, whereas the D47Y mutation may influence normal TRAPP (transport protein particle) dynamics.
INTRODUCTION
SEDT (spondyloepiphyseal dysplasia tarda) is a late-onset X-linked recessive osteochondrodysplasia with a prevalence estimated at ∼ 1.7 per million [1] . SEDT predominantly affects spinal vertebral bodies and epiphyses during skeletal growth, leading to disproportionate dwarfism and a characteristic barrel chest in the second decade of life [2] . SEDT generally affects males only, as heterozygous carrier females are clinically and radiographically normal [2] [3] [4] , although some phenotypic changes have been documented in female carriers [4] . The epiphyseal dysplasia can lead to premature secondary osteoarthritis predominantly affecting the spine and hip joints [5] , often requiring hip replacement [6] , and resulting in significant morbidity [2] .
The X-linked recessive nature of inheritance was first noted in 1939 [7] , but it was not until recent years that the genetics were better understood. After initial linkage studies established that the causative gene lies in the distal part of the short arm of the X chromosome in Xp22 [8, 9] , the candidate causative gene was successfully identified in 1999 and designated SEDL [10] , coding for the protein sedlin. SEDL is located at human chromosome Xp22.12-Xp22.31 [8] [9] [10] [11] , and includes six exons spanning approx. 20 kb of genomic DNA [12] . Further detailed analysis of unrelated cases of SEDT revealed a varied spectrum of mutations present within the SEDL ORF (open reading frame), including nonsense mutations, missense mutations, deletions, insertions and splicing errors [10] . Various mutations essentially resulted in an apparent loss of function, and a complete unaltered sedlin protein was absolutely essential for normal bone growth [13] .
Northern blot analysis and RT (reverse transcription)-PCR experiments revealed ubiquitous expression of both SEDL with a transcript size of approx. 2.8 kb, and also of a transcribed retropseudogene of 0.75 kb on chromosome 19 designated SEDLP1 [10] . There are only six nucleotide differences in the ORFs of the two sequences, but the encoded amino acid sequences are identical. Sedlin is a 140-amino-acid protein, and, although its function is not entirely clear in higher eukaryotes, a number of leads as to function can be inferred. Sedlin is highly conserved with orthologues identified in yeast, fruitflies and vertebrates [10] . The yeast sedlin orthologue, Trs20p, shows 34 % identity with sedlin, and is a member of a large multiprotein complex called TRAPP (transport protein particle), involved in ER (endoplasmic reticulum)-Golgi transport. Tagged recombinant mammalian sedlin was observed in Cos-7 cells to localize with perinuclear structures partly overlapping with the intermediate ER-Golgi compartment, entirely consistent with a similar role for mammalian sedlin in ER-Golgi transport [12] . Trs20p is absolutely essential to yeast, and, intriguingly, it was shown that human WT (wild-type) sedlin was able to rescue lethality, whereas some SEDT mutations were unable to rescue the trs20Δ phenotype [14] . These experiments showed at the very least there has been strong conservation of function of sedlin and Trs20p.
A new perspective on sedlin function was provided by solution of the crystal structure of mouse sedlin [15] . The crystal Abbreviations used: ConA, concanavalin A; DAPI, 4 ,6-diamidino-2-phenylindole; DIG, digoxigenin; DMEM, Dulbecco's modified Eagle's medium; DMF, dimethylformamide; ER, endoplasmic reticulum; FRET, fluorescence resonance energy transfer; GdmCl, guanidinium chloride; GFP, green fluorescent protein; GM130, Golgi matrix protein 130; GST, glutathione transferase; HRP, horseradish peroxidase; IPTG, isopropyl β-D-thiogalactoside; Ni-NTA, Ni 2+ -nitrilotriacetate; ORF, open reading frame; SEDT, spondyloepiphyseal dysplasia tarda; SNARE, soluble N-ethylmaleimide-sensitive factor-attachment receptor; TMB, 3,3 ,5,5 -tetramethylbenzidine; TRAPP, transport protein particle; VTC, vesicular tubular cluster; WT, wild-type. 1 To whom correspondence should be addressed (email jatanner@hkucc.hku.hk).
structure revealed sedlin occurs as a monomer of mixed α/β-fold structure made up of a central β-sheet, with one side flanked by an N-terminal α-helix and the other side by a Cterminal antiparallel α-helix. Interestingly, the structure was highly similar to the N-terminal regulatory domain of the SNARE (soluble N-ethylmaleimide-sensitive factor attachment receptor) proteins Ykt6p and Sec22b, despite no sequence homology. SNARE proteins generally serve regulatory and adaptor functions through multiple protein-protein interactions [16] . Structures have revealed the details of the precise molecular architecture of the entire TRAPPI complex, and sedlin clearly interacts with Bet3 and Trs31 within the complex [17] . To date, 32 different SEDL gene mutations have been identified in 40 unrelated cases [18] . In an effort to understand the mechanism of disease of SEDT and provide an insight into the function of sedlin, we have investigated the properties of four disease-associated mutant proteins of sedlin: D47Y, S73L, F83S and V130D, in both biochemical and cellular contexts. We show that, whereas the S73L, F83S and V130D mutations generally result in protein misfolding and consequent proteasomal degradation, the D47Y mutation folds correctly and has an impact on binding to a further TRAPP component subunit Bet3. Our results both provide insight into the biochemical mechanism of disease for SEDT and strengthen our understanding of sedlin role within the TRAPP complex.
EXPERIMENTAL

Reagents
Mouse Sedl cDNA in the pET15b vector (Novagen) was a gift from Dr S.B. Jiang and Professor B.H. Oh at the University of Pohang in Korea (Pohang, South Korea). Plasmids containing Bet3 were a gift from Professor Wanjin Hong at the Institute of Molecular and Cell Biology (IMCB), Singapore. The plasmids pGEX4T-1 (Amersham Biosciences), pEGFP-C2 (Clontech) containing the GFP (green fluorescent protein) gene under CMV (cytomegalovirus) and pDsRed-Monomer-C1 vector (Clontech) containing the red fluorescent protein gene were propagated in the bacterial strain DH5α and purified using Qiagen plasmid kits. The QuikChange site-directed mutagenesis kit was purchased from Stratagene. Anti-RecA monoclonal antibody and HRP (horseradish peroxidase)-conjugated goat anti-rabbit antibody were purchased from Stressgen Biotechnologies and Invitrogen respectively. DAPI (4 ,6-diamidino-2-phenylindole) was purchased from Sigma. GM130 (Golgi matrix protein 130), ConA (concanavalin A) conjugates and Texas Red goat antimouse IgG were purchased from Affinity BioReagents, Molecular Probes and Invitrogen respectively. FuGENE TM 6 transfection reagent and DMEM (Dulbecco's modified Eagle's medium) were purchased from Roche and Gibco BRL respectively. MG132 (benzyloxycarbonyl-leucylleucylleucinal) was purchased from Calbiochem. A Centricon filter unit with a molecularmass cut-off of 10 kDa was purchased from Millipore. DMF (dimethylformamide) and dansyl chloride were purchased from Sigma and Molecular Probes respectively.
In situ hybridization
The in situ probe for Sedl was generated based on the mouse Sedl gene, a probe that only hybridizes to Sedl mRNA. To generate the Sedl probe, we designed oligonucleotide primers that span a 870 bp region of the 3 untranslated region of the Sedl gene. PCR was performed on a BAC (bacterial artificial chromosome) clone containing the mouse Sedl gene, and an 870 bp product was obtained. The amplified fragment was then ligated into pBluescript II KS + vector (Stratagene) via the SmaI and EcoRV cloning sites. The antisense riboprobe was produced by linearizing the plasmid with BamHI and using T3 RNA polymerase in the presence of DIG (digoxigenin)-UTP, and the sense probe was produced by linearizing the plasmid with HindIII and using T7 RNA polymerase under the same conditions. For hybridization, tissues were fixed in 4 % (w/v) paraformaldehyde, dehydrated, then embedded in paraffin. Sections of 5 μm were cut and placed on microscope slides. The tissue sections were deparaffinized and rehydrated through ethanol series. The sections were then treated with 15 μg/ml proteinase K and acetylated with 0.25 % acetic anhydride. Hybridization was carried out overnight at 53
• C with Sedl riboprobe (1:200 dilution). The sections were washed in 50 % formamide in 2× SSC (1× SSC is 0.15 M NaCl/0.015 M sodium citrate), treated with 20 μg/ml RNase A and washed again with 50 % formamide in 2× SSC followed by 30 % formamide in 2× SSC and 0.1× SSC. The sections were blocked with 1 % blocking reagent followed by incubation of anti-DIG-AP (alkaline phosphatase) antibody (1:500 dilution) overnight at 4
• C. Signal was developed by using NBT (Nitro Blue Tetrazolium)/BCIP (5-bromo-4-chloroindol-3-yl phosphate) substrate solution.
Immunohistochemistry
Tissue sections were quenched for endogenous peroxidase by incubation with 3 % H 2 O 2 for 10 min and blocked with serumfree protein block (Dako) for 20 min. After that, rabbit polyclonal anti-Sedlin antibody (Covalab) was applied to the sections at dilution of 1:3000 and incubated overnight at 4
• C. Secondary goat anti-rabbit antibody conjugated to HRP (Dako) was applied to the same section for 1 h. Staining was developed with DAB (diaminobenzidine) (Dako), substrate and sections were counterstained with haematoxylin. For a negative control, the same dilution of rabbit pre-bleed serum replaced the primary antibody.
Cell culture
Cos-7 and MCT cell lines were cultured in 75-cm 2 flasks in DMEM supplemented with 10 % FBS (fetal bovine serum), 50 μg/ml penicillin and 50 μg/ml streptomycin at 37 and 32
• C respectively in a humidified 5 % CO 2 -containing atmosphere.
Construction of Sedl mammalian expression vector
The mouse Sedl cDNA was inserted into the pEGFP-C2 vector and the mutants were obtained using the QuikChange sitedirected mutagenesis kit. The mouse Sedl cDNA from the pBluescriptIIKS(+/−) vector, incorporating EcoR1 and ApaI sites, was ligated into the pEGFP-C2 vector. These constructs were sequenced to confirm the correct identity and the orientation of the subcloned fragments.
Transfection of cells
Cells from exponential growth phase were seeded at 2 × 10 6 cells per well into six-well plates the day before transfection. For FuGENE TM 6-mediated transfection, the protocol provided by Roche was followed. In the present study, we used 1 μg of DNA to 3 μl of FuGENE TM 6 transfection reagent. Cells were incubated with DNA-FuGENE TM 6 complexes in serum-free medium for 24 h, and fluorescence microscopy was used to observe the efficiency of transfection. For degradation studies, 5 μM MG132 was added to each well after 20 h of transfection. Co-transfection with 0.5 μg of DSRed vector was used as a control for the transfection efficiency in the transfections with various sedlin mutant constructs.
Confocal microscopy
Cells were seeded on sterile coverslips in six-well plates then transfected with Sedl-EGFP fusion constructs as described above. At 24 h post-transfection, cells were washed with PBS and fixed with ice-cold 50 % methanol/50 % acetone for 5 min. After washing, cells were blocked for 60 min in PBS containing 3 % BSA and then incubated for 1 h with primary antibody (anti-GM130) diluted 1:200 in blocking buffer. Cells were then incubated with Texas Red-conjugated anti-mouse IgG (1:200) for 1 h with DAPI and mounted with 50 μl of VectaShield (Vector Laboratories). Microscopy was performed using a Carl Zeiss LSM510 Meta confocal microscope.
Protein expression using Escherichia coli expression system
The mouse cDNA for the Sedl gene was subcloned into the pGEX4T-1 vector. Mutants (D47Y, S73L, F83S and V130D) in the pET15b and pGEX4T-1 vectors were generated using the QuikChange site-directed mutagenesis kit. Target mutations were confirmed by direct DNA sequencing. Each construct was transformed into BL21(DE3) cells. The WT sedlin and its mutants were expressed with either a His 6 tag or a GST (glutathione transferase) tag fused at the N-terminus. Expression of the recombinant sedlin protein was induced by 0.5 mM IPTG (isopropyl β-D-thiogalactoside) at a D 600 of 0.5-0.6 at 298 K for a further 6 h. Cells were harvested at 10 574 rev./min for 20 min using a JA10.5 rotor.
Western blotting
Blots were carried out using a primary antibody raised in rabbit against the C-terminal sequence NPFYEPNSPIRSSA. HRPconjugated goat anti-rabbit antibody was used as a secondary antibody. RecA was used as an internal control with anti-RecA as primary antibody.
Protein purification
Bacterial lysates were sonicated in 50 mM Tris/HCl (pH 6.8) with 100 mM NaCl. The His 6 -tagged fusion protein bound to a Ni-NTA (Ni 2+ -nitrilotriacetate) column (Invitrogen) was eluted with lysis buffer containing 200 mM imidazole after washing the column with the buffer containing 50, 100 and 150 mM imidazole. The eluted fractions were dialysed against sonication buffer and digested with thrombin (Roche Molecular Biomedicals) at a fusion protein/thrombin weight ratio of 20:1 for 12 h at room temperature (25
• C). The digest mixture was loaded on to a gelfiltration column (Sephadex G-50, fine from Sigma) in order to separate the His 6 tag from the protein. The purified protein was at least 95 % pure based on SDS/PAGE analysis.
CD spectroscopy analysis
CD spectra were collected using a Jasco spectropolarimeter. Each purified protein (WT and D47Y) was diluted to a concentration of 25 μM in a buffer containing 20 mM Tris/HCl at pH 6.8. Measurements were taken using a quartz cuvette with a path length of 0.1 mm at room temperature. Spectral scans were performed from 250 to 190 nm with a step resolution of 0.4 nm, a speed of 20 nm/min and a bandwidth of 1.0 nm. Experimental data are shown as an average for three individual experiments. The best fitted spectra and the relative percentages of secondary structures were determined using the CDFIT Program [19] .
Tryptophan fluorescence analysis
Each purified protein (WT and D47Y) was diluted to 5 μM in 20 mM Tris/HCl at pH 6.8. The spectra were recorded using a Jasco fluorimeter. The excitation wavelength was 295 nm and the emission spectra for each protein was recorded from 320 to 400 nm with slit size of 10 nm, a speed of 240 nm/min and response time of 0.1 s.
Protein folding studies
For the unfolding measurements, WT and D47Y purified sedlin protein (2 μM) were incubated overnight at various concentrations of GdmCl (guanidinium chloride) (0-4 M) containing 20 mM Tris/HCl at pH 6.8. The unfolding of the protein was monitored by intrinsic tryptophan fluorescence at room temperature (excitation wavelength was 295 nm and the emission spectra were recorded from 300 to 400 nm). An unfolding transition curve was obtained by plotting the wavelength of maximum tryptophan fluorescence against GdmCl concentration. For the refolding studies, each protein (approx. 20 μM) was incubated in 4 M GdmCl for 24 h, then refolding was performed by a 10-fold dilution of the protein in different concentrations of GdmCl (0.4-3 M). The protein samples were incubated overnight at room temperature and the intrinsic tryptophan fluorescence of each sample was recorded.
Thermal melting experiment using CD
CD measurements were performed on a J810 spectropolarimeter (Jasco) equipped with a Jasco PTC-4235 temperature controller. CD spectra of WT and D47Y sedlin (25 μM) were measured in 1-mm-pathlength quartz cuvettes. The temperature was measured with a thermocouple element glued to the outside of the cuvette. Each spectrum was recorded and corrected by subtracting the buffer spectrum. The temperature was manually increased within the range 25-70
, and the machine recorded the signal at 222 nm every 1/10 min. Experimental data are shown as an average for three individual experiments.
Pull-down analysis of sedlin and Bet3 interaction
Purified GST-WT sedlin or GST-D47Y sedlin was bound to saturation on a GST column, then excess purified His 6 -Bet3 was passed through the column. The protein was washed, then 50 mM reduced glutathione in PBS was used to elute the complex. As a secondary approach, purified His 6 -Bet3 proteins were bound to an Ni-NTA column, then either excess GST-WT sedlin or GST-D47Y sedlin was allowed to pass through the column before elution with imidazole as described above. All eluates were analysed by SDS/PAGE.
Fluorescence labelling with dansyl chloride and FRET (fluorescence resonance energy transfer) studies
Purified Bet3 protein was dialysed against 0.1 M sodium bicarbonate buffer (pH 7.0) overnight. Then the protein was concentrated to 10 mg/ml using a Centricon filter unit. Then, 1 ml of the Bet3 protein was mixed with 75 μl of dansyl chloride solution (1 mg/ml in DMF) in the dark at 4
• C continuously for 1 h. The unreacted labelling reagent was separated from the conjugate using a gel-filtration column (Sephadex G-50, fine). The protein conjugate was collected from the column, analysed by SDS/PAGE and stored at 4
• C in the dark before use. Purified sedlin protein (WT and D47Y) and labelled Bet3 were dialysed against PBS before use. FRET measurements were performed using Bet3 labelled with dansyl chloride as the acceptor fluorophore at the N-terminus, with the tryptophan residues in WT or D47Y sedlin protein serving as the donor fluorophore. Purified WT and D47Y sedlin protein (0.05 μM) were incubated with various concentrations of labelled Bet3 protein (0-6 μM) in PBS at room temperature before measurement. Emission spectra were measured at room temperature in a Jasco fluorimeter with slit size of 5 nm, a speed of 240 nm/min, PTM of 950 V and response time of 0.1 s. Then the fluorescence emission from tryptophan in the sedlin protein was measured at 331 nm with excitation at 295 nm. Readings are given as the average of three separate measurements. K d values for binding of WT and D47Y mutant sedlin to Bet3 were obtained using Origin 6.1. A simple single-site Michaelis-Menten model binding was used to plot the changes of wavelength of maximum tryptophan fluorescence (peak at 331 nm) against Bet3 concentration. • C on a plate vortex, shaking gently. Excess biotinylated Bet3 proteins was added in an empty well to act as a control. The wells were washed extensively four times with 200 μl of wash buffer for 5 min each on a plate vortex. Streptavidin-HRP (Molecular Probes) was diluted 1:100000 in PBS, and a 200 μl aliquot was incubated with the mixture in the HisSorb plate for 30 min at room temperature. The wells were washed again as described above, then 100 μl of Turbo-TMB (3,3 ,5,5 -tetramethylbenzidine) (Pierce) was added to each well and incubated for 20 min at room temperature in the dark. The reactions were stopped with the addition of 100 μl of 1 M H 2 SO 4 , and the sedlin-bound Bet3-streptavidin complex was quantified by determining the absorbance at 450 nm using a SpectraMax Plus (Molecular Devices). Readings are given as the average of three separate measurements. Apparent K d values for the interaction between Bet3 and WT or D47Y sedlin proteins were determined using Origin 6.1. A simple single-site MichaelisMenten model binding was used to plot the readings at A 450 against the Bet3 concentration.
RESULTS
Sedlin is expressed principally in chondrocytes in the mouse growth plate
Previous studies showed that SEDL is expressed in multiple tissues, including heart, brain, skeletal muscle and other tissues, by Northern blot hybridization [10] . However, there is no detailed knowledge of the major cell types that express sedlin in cartilage and bone despite the phenotype of SEDT. To investigate where sedlin is expressed in cartilage growth plate, we performed both in situ hybridization using a riboprobe specific for Sedl in mouse growth plates and also immunohistochemistry. We showed that Sedl is expressed predominantly in chondroctyes at various stages of differentiation, including proliferating, prehypertrophic and hypertrophic chondrocytes in the distal femoral joint growth plate ( Figures 1A and 1B) . A control of the sense riboprobe of Sedl is shown in Figures 1(C) and 1(D) . Expression of Sedl was also observed in other growth plates, including ribs, sternum, vertebral bodies and long bones (results not shown). Immunohistochemistry also showed the presence of sedlin protein in chondrocytes at every stage of differentiation ( Figures 1E and 1F) .
Mutation of sedlin affects subcellular localization
Four missense mutations have been observed in patients with SEDT: D47Y, S73L, F83S and V130D (Figure 2A) . In order to investigate the subcellular localization of WT sedlin and its mutants, the cDNA of mouse sedlin and the mutants was cloned into pEGFP vectors for N-terminal GFP fusions. The plasmids were transiently transfected into Cos-7 cells to investigate localization by Western blotting and by confocal microscopy. Western blotting revealed WT sedlin to be present in both soluble cytoplasmic fraction and in the membrane fraction ( Figure 2B , lane 1). The D47Y sedlin showed similar protein levels in the cytoplasmic fraction, but lower levels in the membrane fraction ( Figure 2B , lane 2). The S73L sedlin showed very low protein expression levels generally in both fractions ( Figure 2B, lane 3) , and the F83S and V130D sedlin mutants were present in the cytoplasm yet had even lower expression in the membrane fraction than D47Y sedlin ( Figure 2B , lanes 4 and 5). We also performed confocal microscopy studies using the Golgi marker GM130, the nuclear marker DAPI, and the GFP signal from the sedlin. WT sedlin was mainly expressed in granular structures around the nucleus and in the vicinity of the Golgi, with weak expression generally throughout the cytoplasm ( Figure 2C, panel i) . These results were consistent with those reported previously [12] . D47Y sedlin showed similar cytoplasmic expression, but lost its expression in the granular structures ( Figure 2C , panel ii), consistent with the Western blot results. S73L sedlin was expressed, but at low levels generally ( Figure 2C , panel iii). F83S and V130D sedlin did retain cytoplasmic expression ( Figure 2C , panels iv and v). The results for the localization were generally consistent between the Western blot and the confocal study: WT sedlin localizes to both the cytoplasm and granular structures around the nucleus, S73L expresses at a low level, D47Y is present at a lower level in the granular structures, and F83S and V130D are at far lower levels in the granular structures.
S73L, F83S and V130D sedlin mutations result in proteasomal degradation of misfolded protein
Our results suggested the mutations in sedlin may lead to significant problems in folding. Protein misfolding may lead to degradation via the proteasomal degradation pathway immediately, resulting in very low protein expression signals. To test this hypothesis, we used the proteasome inhibitor MG132 to block the proteasomal degradation pathway. WT and D47Y sedlin showed little difference in fluorescence in the presence and absence of MG132 ( Figure 2D ). In the absence of MG132, S73L, F83S and V130D showed levels of fluorescence far lower than that of the WT or D47Y protein ( Figure 2D ). However, after adding MG132, their expression recovered to levels approaching that of WT and D47Y sedlin ( Figure 2D ). As a control for the transfection efficiency, co-transfection with DSRed vector showed no differences in the transfection efficiency of the vector between the various sedlin mutants ( Figure 2E ). DSRed protein expression also showed no difference in red fluorescence signals in the presence and absence of MG132 ( Figure 2E ). Moreover, we also performed confocal microscopy studies using the ER marker ConA (in red in Figure 2F ), Golgi marker GM130 (in red in Figure 2G ) and the nuclear marker DAPI (in blue in Figures 2C, 2F and 2G) to monitor the expression of the mutant sedlin (in green in Figures 2C, 2F and 2G) before and after adding MG132. Confocal microscopy revealed that the S73L, F83S and V130D mutants were visualized in the ER in the presence of MG132 (results for F83S are shown as a representative result in Figures 2F and 2G ) as expected for proteins destined for the proteasomal degradation pathway. These degradation studies provide strong evidence that the S73L, F83S and V130D mutants affect the folding of the protein, and that inhibition of proteasomal degradation leads to retention of the mutant protein in the ER.
Both the WT and D47Y sedlin proteins are able to fold correctly, whereas S73L, F83S and V130D are unable to fold in prokaryotic expression systems Sedlin has previously been expressed for structural studies in E. coli [15] , so we therefore investigated comparative expression in this prokaryotic system. We prepared plasmids coding for each mutant protein by point mutagenesis on the WT sedlin plasmid. We subcloned into two prokaryotic expression vectors to confirm that the tag had no extrinsic effect on folding. We expressed from both pET15b carrying an N-terminal His 6 tag and from pGEX4T-1 carrying an N-terminal GST tag. We then induced expression using IPTG, harvested cells, sonicated, separated soluble and insoluble fractions by centrifugation and assessed sedlin levels by Western blotting (Figure 3 ). Only WT sedlin and D47Y were expressed in the soluble fraction, although the D47Y mutation did reduce soluble expression slightly ( Figures 3A and 3B, lanes  1 and 2) . However, none of the other mutants S73L, F83S and V130D showed any detectable signals in the soluble fraction, and these three misfolded to become inclusion bodies in the insoluble fraction ( Figures 3A and 3B, lanes 3, 4 and 5 respectively) .
D47Y folds similarly to the WT protein as investigated by CD and steady-state fluorescence
In order to obtain significant amounts of proteins for biophysical studies, we purified both WT and D47Y His 6 -tagged sedlin. Bacterial lysates were prepared by sonification, then the His 6 -tagged fusion sedlin protein was bound to an Ni-NTA column and eluted with 230 mM imidazole. After purification of the protein, the N-terminal His 6 tag from the protein was removed by thrombin cleavage then purified by gel filtration (see Supplementary Figure S1 at http://www.BiochemJ.org/bj/423/ bj4230233add.htm). Approx. 1 mg of pure sedlin was obtained from 2 litres of bacterial culture.
Using the purified WT and D47Y sedlin we used CD and steadystate fluorescence to determine the protein secondary structure. The CD spectra of WT sedlin and its D47Y mutant are very similar ( Figure 4A ), suggesting that the D47Y mutation does not change the secondary structure of the protein. Analysis of the CD spectra using the CDFIT program predicted 37.6 % α-helix and 26.5 % β-strand for WT sedlin, which is consistent with the mouse sedlin crystal structure (38 % α-helix and 25 % β-strand) [15] . Fitting of the D47Y CD data also revealed general similarities of D47Y to the WT with slightly less β-strand structure for D47Y (37.7 % α-helix and 21.5 % β-strand for D47Y compared with 37.6 % α-helix and 26.5 % β-strand for WT). Steady-state fluorescence is a useful probe for the solventaccessibility of tryptophan side chains. This technique is particularly appropriate in this case as the protein only has two tryptophan residues, Trp 54 and Trp 70 , and Trp 54 is in the vicinity of the amino acid change D47Y. Significant changes in solventaccessibility of these tryptophan residues would result in consequent changes in fluorescence. However, consistent with the CD results, the D47Y mutant had virtually an identical fluorescence emission spectrum with that of the WT protein, suggesting there were no major changes in secondary structure caused by this mutation ( Figure 4B ).
D47Y shows similar stability to the WT sedlin by unfolding studies
We investigated the unfolding of proteins using the chaotrope GdmCl as an approach to measure the relative stability of the D47Y mutant. As shown in Figure 4(C) , an unfolding transition curve was obtained by plotting the wavelength of maximum tryptophan fluorescence against GdmCl concentration. Without denaturant, the maximum tryptophan fluorescence for WT and D47Y were 330.8 and 330.4 respectively, suggesting there is a very slight change in structure between WT and D47Y sedlin. Unfolding leads to a red-shift in the emission maxima as the tryptophan residues become more exposed to the solvent during unfolding. Our results showed no significant differences in stability between the WT sedlin and its D47Y mutant (50 % unfolding occurs at 0.86 + − 0.1 and 1.02 + − 0.05 M GdmCl for WT and D47Y respectively, within experimental error of each other). Moreover, our results showed that the GdmCl concentration for reversible refolding of both denatured WT and D47Y also gave very similar results ( Figure 4C ). Thus, on the basis of the unfolding and refolding studies, the stability of sedlin is not affected by the D47Y mutation.
We also performed CD measurements to investigate thermal stability using a spectropolarimeter equipped with a temperature controller. In the experiment, CD spectra of sedlin WT and D47Y protein (25 μM) were measured at 222 nm with the temperature increased within the range 25-70 Figure 4D ). Fitting of three independent experiments using a Boltzmann function gave T m values of 51.3 + − 1.1
• C for WT sedlin and 50.5 + − 0.8
• C for D47Y sedlin. Thus our results showed no significant differences in thermal stability between the WT and D47Y sedlin protein.
D47Y interacts more strongly with the TRAPP component Bet3 than WT sedlin
Previously published studies have shown that mBet3 interacts with mTrs20 (mammalian sedlin) in vitro [21] . We therefore investigated the impact of the D47Y mutation on the interaction of sedlin with Bet3. We used independent GST pull-down assays and His 6 pull-down assays to investigate the interaction. In the GST pulldown, we initially saturated a glutathione-Sepharose column with GST-sedlin or GST-D47Y sedlin. Subsequently, excess His 6 -Bet3 was passed through the column, the column was washed, and then the complex was eluted ( Figure 5A ). It was observed that His 6 -Bet3 bound to both GST-sedlin and GST-D47Y sedlin, with the GST-D47Y sedlin interaction being potentially stronger. To validate this finding, we saturated an Ni 2+ -affinity column with excess His 6 -Bet3. We then passed an excess of either GST-sedlin or GST-D47Y sedlin over the column, which was washed then eluted. Again, it was observed that, whereas both GST-sedlin and GST-D47Y sedlin bound to His 6 -Bet3, the interaction was potentially stronger for GST-D47Y sedlin ( Figure 5B ).
To confirm this qualitative result, we performed two independent quantitative experiments to measure directly the strength of binding of Bet3 to WT or D47Y sedlin. First, Bet3 was labelled at its N-terminus with dansyl chloride, which acts as an acceptor fluorophore for FRET from the tryptophan residues in WT or D47Y sedlin. Thus we were able to observe binding by a decrease in tryptophan fluorescence when Bet3 was titrated against sedlin ( Figure 5C ). By fitting our titration data to a simple single-site Michaelis-Menten model, the affinity between Bet3 and WT sedlin was measured to be 1.07 + − 0.07 μM, whereas the affinity between Bet3 and D47Y sedlin was measured to be 0.39 + − 0.02 μM. Thus D47Y binds more strongly to Bet3 than WT sedlin.
As a second quantitative method of validation, we used a variation of a solid-phase binding assay similar to one previously reported with modifications [21] . The principle of this assay is that one protein is immobilized, the interacting partner is covalently labelled with biotin, the labelled partner is incubated with the immobilized protein, the surface is washed, then the quantity of biotin-labelled interacting partner is quantified by an HRP-linked assay. His 6 -tagged WT sedlin or D47Y sedlin were immobilized on an Ni 2+ -coated plate, then incubated with various concentrations of biotinylated Bet3. Sedlin-bound biotinylated Bet3 was then quantified using streptavidin-HRP by monitoring the absorption of oxidized TMB. Experiments were performed in triplicate and fitted to a Michaelis-Menten model ( Figure 5D ). The apparent K d for WT sedlin was 3.2 + − 0.9 μM and the apparent K d for D47Y sedlin was 1.3 + − 0.1 μM.
Variations in the exact values of the K d values are expected given that one assay is solution-phase and the other is solid-phase. Our data from both our qualitative and two independent quantitative experiments were consistent in showing that the mutant D47Y sedlin bound more strongly to Bet3 than the WT sedlin.
DISCUSSION
The present study has documented the impact of four different point mutations in the protein sedlin that lead to SEDT. Although D47Y was found to express, fold and have general biophysical characteristics and stability similar to the WT protein, the other three mutants S73L, F83S and V130D all misfolded. S73L, F83S and V130D misfolded and entered inclusion bodies on attempted expression in E. coli, and entered the proteasomal degradation pathway when expressed in mammalian cells. D47Y did show slightly different localization from that of the WT with higher general cytoplasmic expression. Surprisingly, D47Y was shown to have a stronger interaction with the TRAPP component Bet3 than WT sedlin.
Our results can be put into context by observing the location of each of these amino acids in the crystal structure of sedlin [15] , and also within published structures of the entire TRAPPI complex [17] . Asp 47 is a surface-exposed residue at the end of the N-terminal α-helix in a highly conserved stretch of amino acids that has been suggested to be an exposed site of protein-protein interaction [15] . Indeed, Asp 47 is invariant and entirely conserved from yeast to human [15] . The change in charge by mutating the aspartate residue to tyrosine we show to strengthen the interaction of WT sedlin with another TRAPP component Bet3. This is somewhat surprising in the light of electron microscopy structures of the TRAPPI complex that show that, although there is an interaction between sedlin and Bet3, Asp 47 is an exposed residue, and mutation was postulated to interfere with a potential SNARE interaction [17] . Nevertheless, it is conceivable that the mutation may affect the strength of the Bet3 interaction, and perhaps this effect may be clearer in the physiologically relevant tertiary sedlin-Bet3-Trs31 complex. However, the main pathological mechanism for the D47Y mutation may also be due to disruption of a further protein-protein interaction as postulated previously [17] . Ser 73 , Phe 83 and Val 130 are all at sites that are structurally important, yet are inaccessible to solvent [15] . Ser 73 is involved in an hydrogen-bonding network that would be disrupted by the mutation to leucine, and Phe 83 and Val 130 are both highly conserved buried hydrophobic residues that we have shown lead to misfolding as a result of the F83S or V130D mutations.
Much progress has been made in improving structural and functional understanding of the TRAPP complex. Bet3 has been shown to have strong self-palmitoylating activity [22] , to form part of the core of the TRAPP complex together with Tpc6B [23] , and has been shown to play a critical role in the organization of the TRAPP complex both in mammalian cells and in yeast [21] . Furthermore, mammalian Bet3 was previously shown to localize to the transitional ER and adjacent VTCs (vesicular tubular clusters) [24] . Inactivation of mBet3 was shown to block COPII (coatamer protein II) vesicle tethering, implicating mBet3 in VTC biogenesis [24] . It was also shown that the two TRAPPII-specific subunits Trs120 and Trs130 switch the complex's GEF (guaninenucleotide-exchange factor) activity from Ypt1 to Ypt31/32 [25] . It is also interesting to note that defects in the Trappc6a gene (mammalian counterpart of Trs33p) resulted in a mosaic loss of coat pigment in mice [26] , implicating this subunit in vesicle trafficking during melanosome biogenesis, a process which carries many similarities to export of the extracellular matrix in chondrocytes.
Furthermore, our data show for the first time that sedlin is expressed predominantly in chondrocytes in the mouse growth plate. In light of the clinical phenotype of spondyloepiphyseal dysplasia, it is not surprising as many other chondrodysplasias are caused by defects in expression within chondrocytes at various stages of differentiation including Schmid metaphyseal dysplasia, multiple epiphyseal dysplasia and dyssegmental dysplasia [27] . We also observed that sedlin was expressed early in prenatal development (results not shown), suggesting that the late-onset phenotype of SEDT is not caused by late-onset expression of the gene. Although we have not directly addressed why SEDT is a late-onset disease, our experiments suggest this is not due directly to temporal expression of sedlin, but is more likely to be due to an extrinsic factor such as functional redundancy early in life with the retropseudogene on choromosome 19 encoding an identical protein [10, 12, 28, 29] . Another challenge which has previously been discussed [29] is determining the reasons that SEDT is a tissue-specific disease. Using in situ hybridization in mice, we have confirmed previous reports [10, 30] that SEDT is ubiquitously expressed in multiple tissues (results not shown). Our results comparing the expression of sedlin in Cos-7 cells with chondrocyte cell lines showed broadly similar results in terms of localization of expression of both WT and mutant sedlin, suggesting that the mechanism of sedlin-mediated vesicle transport is similar in the two cell lines. The tissue-specific phenotype may also be caused by the tissue-specific expression of the pseudogene, or by the tissue-specific expression of interacting partners of sedlin beyond the TRAPP complex. Experiments are ongoing to investigate these hypotheses.
To conclude, the D47Y sedlin mutation influences TRAPP dynamics, whereas the S73L, F83S and V130D sedlin mutations all abrogate sedlin folding, resulting in effective loss of sedlin function leading to SEDT. Further studies to investigate the late-onset nature and tissue-specificity of the disease will potentially identify therapeutic targets for this debilitating osteochondrodysplasia.
